Brixadi
Brixadi 1ML of 128MG/0.36ML
What is Brixadi?
Brixadi (buprenorphine) is a once-weekly or once-monthly extended-release injectable medication approved for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a transmucosal buprenorphine-containing product. It functions primarily as a partial agonist at opioid receptors, helping to prevent withdrawal symptoms and reduce opioid cravings. Brixadi is intended to be used as part of a comprehensive treatment plan that includes counseling and psychosocial support.Side Effects
- Nausea
- Headache
- Dizziness
Warnings
- Risk of opioid addiction, abuse, and misuse, which can lead to overdose and death
- Serious, life-threatening, or fatal respiratory depression may occur
- Accidental ingestion can result in a fatal overdose of buprenorphine
- Neonatal opioid withdrawal syndrome may occur in newborn infants of mothers who are treated with buprenorphine during pregnancy
- Concomitant use with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death
Prescription savings · · ·
- Nausea
- Headache
- Dizziness
- Constipation
- Vomiting
- Sweating
- Sleep disturbances
- Risk of opioid addiction, abuse, and misuse, which can lead to overdose and death
- Serious, life-threatening, or fatal respiratory depression may occur
- Accidental ingestion can result in a fatal overdose of buprenorphine
- Neonatal opioid withdrawal syndrome may occur in newborn infants of mothers who are treated with buprenorphine during pregnancy
- Concomitant use with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death
Brixadi Coupons & Prices
Brixadi 1ML of 128MG/0.36ML
What is Brixadi ?
Brixadi (buprenorphine) is a once-weekly or once-monthly extended-release injectable medication approved for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a transmucosal buprenorphine-containing product. It functions primarily as a partial agonist at opioid receptors, helping to prevent withdrawal symptoms and reduce opioid cravings. Brixadi is intended to be used as part of a comprehensive treatment plan that includes counseling and psychosocial support.
Related Drugs
Browse more medications: starting with B · full A-Z directory · by condition · common drugs
Medical disclaimer: This information is provided for general educational purposes only and is not medical advice. It is not a substitute for professional diagnosis or treatment. Always consult a licensed physician, pharmacist, or other qualified healthcare provider before starting, stopping, or changing any medication or treatment. Never disregard professional medical advice or delay seeking it because of something you read here. If you think you may have a medical emergency, call your doctor or 911 immediately.